TriangleNCT02867592 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of patients
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 1 year
What was measured
The 1-year Overall Survival will be estimated using Kaplan-Meier methodology.
Analysis population: All patients who met the evaluable for response criteria outlined in section 9.4 of the ADVL1622 protocol.
Groups in this outcome
Ewing's Sarcoma
Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Rhabdomyosarcoma
Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Non-Rhabdomyosarcoma Soft Tissue Sarcoma
Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Wilms Tumor
Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Rare Tumors
Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Osteosarcoma
Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Ewing's Sarcoma | 13 |
| Rhabdomyosarcoma | 13 |
| Non-Rhabdomyosarcoma Soft Tissue Sarcoma | 13 |
| Wilms Tumor | 13 |
| Rare Tumors | 23 |
| Osteosarcoma | 29 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ewing's Sarcoma | 53.85 | Not reported | 24.77 | 75.99 | Not reported |
| Rhabdomyosarcoma | 25 | Not reported | 6.01 | 50.48 | Not reported |
| Non-Rhabdomyosarcoma Soft Tissue Sarcoma | 74.59 | Not reported | 39.76 | 91.10 | Not reported |
| Wilms Tumor | 42.74 | Not reported | 15.90 | 67.50 | Not reported |
| Rare Tumors | 34.78 | Not reported | 16.63 | 53.71 | Not reported |
| Osteosarcoma | 35.86 | Not reported | 18.96 | 53.13 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 24.77
- upper Limit
- 75.99
- value
- 53.85
- group Id
- OG001
- lower Limit
- 6.01
- upper Limit
- 50.48
- value
- 25
- group Id
- OG002
- lower Limit
- 39.76
- upper Limit
- 91.10
- value
- 74.59
- group Id
- OG003
- lower Limit
- 15.90
- upper Limit
- 67.50
- value
- 42.74
- group Id
- OG004
- lower Limit
- 16.63
- upper Limit
- 53.71
- value
- 34.78
- group Id
- OG005
- lower Limit
- 18.96
- upper Limit
- 53.13
- value
- 35.86
- denoms
- counts
- group Id
- OG000
- value
- 13
- group Id
- OG001
- value
- 13
- group Id
- OG002
- value
- 13
- group Id
- OG003
- value
- 13
- group Id
- OG004
- value
- 23
- group Id
- OG005
- value
- 29
- units
- Participants
- description
- The 1-year Overall Survival will be estimated using Kaplan-Meier methodology.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Ewing's Sarcoma
- description
- Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG001
- title
- Rhabdomyosarcoma
- description
- Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG002
- title
- Non-Rhabdomyosarcoma Soft Tissue Sarcoma
- description
- Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG003
- title
- Wilms Tumor
- description
- Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG004
- title
- Rare Tumors
- description
- Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG005
- title
- Osteosarcoma
- param Type
- NUMBER
- population Description
- All patients who met the evaluable for response criteria outlined in section 9.4 of the ADVL1622 protocol.
- reporting Status
- POSTED
- time Frame
- Up to 1 year
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- Percentage of patients
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice